Total revenues were $2.5 billion in the September quarter, compared to $2.47 billion last year. For the full year of 2025, the company expects revenues to be flat to up 1%, at constant currency, versus full year 2024.
Net income attributable to Biogen was $466.5 million or $3.17 per share in Q3, compared to $388.5 million or $2.66 per share in the third quarter of 2024. Adjusted earnings increased 18% annually to $4.81 per share in the third quarter.
The management said it expects full-year adjusted earnings per share to be in the range of $14.50 to $15.00, including expected improved business impact of approximately $0.25 EPS, offset by an expected impact in the fourth quarter from acquired IPR&D expenses.
ADVERTISEMENT